Critical Contrast: PTC Therapeutics (NASDAQ:PTCT) & Axsome Therapeutics (NASDAQ:AXSM)

PTC Therapeutics (NASDAQ:PTCT) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Insider & Institutional Ownership

81.5% of Axsome Therapeutics shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Comparatively, 22.4% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

PTC Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Profitability

This table compares PTC Therapeutics and Axsome Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	39.44%	-362.45%	25.21%
Axsome Therapeutics	-28.69%	-232.61%	-25.84%

Valuation and Earnings

This table compares PTC Therapeutics and Axsome Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73 billion	3.12	$682.64 million	$7.74	8.44
Axsome Therapeutics	$638.50 million	12.57	-$183.17 million	($3.69)	-42.53

PTC Therapeutics has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for PTC Therapeutics and Axsome Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	1	4	10	0	2.60
Axsome Therapeutics	2	0	17	0	2.79

PTC Therapeutics presently has a consensus price target of $82.79, suggesting a potential upside of 26.78%. Axsome Therapeutics has a consensus price target of $216.12, suggesting a potential upside of 37.72%. Given Axsome Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than PTC Therapeutics.

About PTC Therapeutics

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

About Axsome Therapeutics

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer’s disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.